Organization · Accelerator
Therapeutics Accelerator
The COVID-19 Therapeutics Accelerator (CTA) is a philanthropic organization focused on developing effective treatments for COVID-19. It collaborates with various stakeholders to accelerate drug development and ensure equitable access to therapeutics.
Overview
What Therapeutics Accelerator does
What Therapeutics Accelerator is
The COVID-19 Therapeutics Accelerator (CTA) is a philanthropic organization focused on developing effective treatments for COVID-19. It collaborates with various stakeholders to accelerate drug development and ensure equitable access to therapeutics.
How it participates in the startup ecosystem
The current public profile supports funder and grantor capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Accelerator
- Structured capabilities
- Funder · Grantor
- Last reviewed
- March 7, 2026
What Accelerator means
An accelerator is a structured, short-term program designed to speed up a startup's progress toward product-market fit, traction, fundraising, or scale.
Open the glossary entryOfficial channels
Find Therapeutics Accelerator elsewhere
Open the official website or a supported primary organization account.
Capability profile
Therapeutics Accelerator as a funder
Investment thesis
The CTA focuses on investing in the research and development of therapeutics for COVID-19, emphasizing equitable access to treatments in low-resource settings.
Focus narrative
The CTA invests in the research and development of therapeutics for COVID-19, focusing on multiple prevention and treatment options. Their approach encompasses drug discovery, clinical trials, manufacturing, and real-world evidence, supporting efforts from drug pipeline development through to manufacturing and scale-up.
Value beyond capital
The CTA provides funding and support for research and development initiatives, facilitating collaboration among stakeholders to ensure the rapid development and equitable distribution of COVID-19 therapeutics.
Terms and economics
- Typical check
- $1,000,000–$50,000,000
- Sweet spot
- $20,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B · Series C
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
The CTA has funded several notable trials and initiatives, including the Henry Ford Health System WHIP Trial, the University of Oxford / Mahidol Oxford Tropical Medicine Research Unit COPCOV Trial, the Washington University CROWN CORONATION Trial, the AGILE – University of Liverpool Phase I/II trial, and the Montreal Heart Institute COLCORONA Trial.
Capability profile
Therapeutics Accelerator as a grantor
Grant thesis
The COVID-19 Therapeutics Accelerator (CTA) is dedicated to accelerating the development of effective treatments for COVID-19 through philanthropic collaboration.
Focus narrative
The CTA invests in the research and development of therapeutics for COVID-19, focusing on multiple prevention and treatment options. Their approach encompasses drug discovery, clinical trials, manufacturing, and real-world evidence, ensuring equitable access to treatments in low-resource settings.
Value and support
Beyond funding, the CTA provides strategic support and coordination with various stakeholders, including the World Health Organization and private sector organizations, to enhance the development and accessibility of COVID-19 treatments.
Grant economics
- Grant range
- $1,000,000–$50,000,000
- Typical grant
- $20,000,000
- Dilutive
- No
- Nonprofit only
- Yes
Availability
- Application state
- Accepting
- Application cycle
- rolling
Eligibility and fit
- Stages
- Accelerator
- Audience
- Researchers
- Sectors
- Healthcare
- Regions
- Global
Process and recipient context
Application process
Organizations interested in funding can apply through the CTA's website. The application process involves submitting proposals that align with the CTA's focus on COVID-19 therapeutics, including drug development and clinical trials.
Recipient context
The CTA has funded notable trials such as the Henry Ford Health System WHIP Trial, University of Oxford's COPCOV Trial, Washington University's CROWN CORONATION Trial, AGILE at the University of Liverpool, and the Montreal Heart Institute's COLCORONA Trial.
Common questions
What to know about Therapeutics Accelerator
Upseed classifies Therapeutics Accelerator under the Accelerator organization type. Its current public profile includes funder and grantor capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 7, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.